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health care services increased from $725,019,395 (mean
= $395; 95% CL = $140–$650) to $3,049,290,075 (mean
= $1,802; 95% CL = $618–$2,987). Total prescription
medication expenditures increased from $941,406,990
(mean = $24; 95% CL = $18–$29) to $1,202,568,785
(mean = $34; 95% CL = $30–$37). Expenditures on
ofﬁce-based medical provider and emergency department
visits showed minor increases while those on outpatient
services exhibited a minor decrease. CONCLUSIONS:
From 1996 to 1999, there was no difference in the preva-
lence of back pain however there was an $11.1 billion
increase in direct costs. Inpatient stays, home care ser-
vices, and prescription medications accounted for the
majority of this increase.
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OBJECTIVES: Gabapentin and topical lidocaine patch
(LIDO) are US FDA approved drugs for treatment of 
postherpetic neuralgia (PHN); tricyclics and opioids are
also frequently used. The cost-effectiveness of drug
therapy (Rx) for PHN is unclear. METHODS: We devel-
oped a Markov decision model to estimate the incremen-
tal cost-effectiveness of 5 management strategies for
established PHN in 70 year olds: no therapy, gabapentin,
LIDO, tricyclic (nortriptyline), or opiod (long acting mor-
phine). The analysis took a societal perspective, using 
reference case recommendations of the Panel on Cost-
Effectiveness in Health and Medicine. We used literature
data for parameter values, assuming that Rx related pain
relief equaled decreased PHN disutility. We also assumed
that gabapentin, nortriptyline, and opiod had identical
side effect likelihood (30%) and severity (possible bias
against gabapentin). One-way and multiway sensitivity
analyses were performed. RESULTS: In the baseline
analysis, nortriptyline is eliminated by extended domi-
nance. Compared to no treatment, opioid costs $60,000
per quality adjusted life year (QALY) gained. Compared
to opioid, gabapentin costs $74,000/QALY. Compared to
gabapentin, LIDO costs $795,000/QALY. In sensitivity
analyses, LIDO is preferred (<$75K/QALY) if pain relief
was >31% (baseline 23.8%) or if only 1 patch is required
(baseline 2). Opiod is not preferred if disutility due to
stigma is associated with its use but is preferred if pain
relief is >33% (base 32.3%). Nortriptyline is preferred if
pain relief is >22.5% (base 19.0%). Gabapentin domi-
nates all other Rx if its side effect frequency is <28%.
Monte Carlo analysis, with variation of all sensitive para-
meters over clinically plausible ranges, conﬁrms greater
economic acceptability of gabapentin. CONCLUSIONS:
In an analysis biased against its use, gabapentin is the
most economically reasonable choice for drug therapy of
established postherpetic neuralgia.
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OBJECTIVE: There is a lack of updated information on
healthcare expenditures and expenditure patterns for
individuals with back pain in the US. The objective of this
study is to use a recently released national survey data-
base to estimate total healthcare expenditures incurred 
by individuals with back pain in the US, calculate the
incremental expenditures attributable to back pain
among these individuals, and describe healthcare expen-
diture patterns of individuals with back pain.
METHODS: This study used data from 1998 Medical
Expenditure Panel Survey (MEPS), a national survey on
healthcare utilization and expenditures. Total healthcare
expenditures and per-capita expenditures among individ-
uals with back pain were calculated. Multivariate regres-
sion models were used to estimate the incremental
expenditures attributable to back pain. The expenditure
patterns were examined by stratifying individuals with
back pain by socio-demographic characteristics and
medical diagnosis, and calculating per-capita expendi-
tures for each stratiﬁed category. RESULTS: In 1998,
total healthcare expenditures incurred by individuals with
back pain in the US reached $90.7 billion and total incre-
mental expenditures attributable to back pain among
these persons were approximately $26.3 billion. On
average, individuals with back pain incurred expenditures
about 60% higher than individuals without back pain
($3495 vs. 2178). Among back pain individuals, at least
75% of service expenditures were attributed to those with
top 25% expenditure and per-capita expenditures were
generally higher for those who were older, female, whites,
medically insured or suffered from disc disorders. CON-
CLUSIONS: Healthcare expenditures for back pain in the
US in 1998 were substantial. The expenditures demon-
strated wide variations among individuals with different
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OBJECTIVE: To compare the drug utilization patterns,
in particular the compliance and persistency of therapy,
